Abcam, ab259224, Human UBE2J2 knockout HEK-293T cell lysate

Size: 1Kit
UBE2J2 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon4.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon4.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-UBE2J2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
UBE2J2 also known as UBC6e is an E2 ubiquitin-conjugating enzyme with a molecular mass of around 35 kDa. It is involved in the ubiquitination process transferring ubiquitin from an E1 activating enzyme to a substrate often marking the substrate for degradation by the proteasome. UBE2J2 localizes primarily in the endoplasmic reticulum (ER) membrane but you can also find it distributed in other cellular membranes.
Biological function summary
The ubiquitin-conjugating enzyme UBE2J2 plays a role in protein quality control helping in the ER-associated degradation (ERAD) pathway. This process is important for maintaining cellular homeostasis by degrading misfolded or improperly assembled proteins. UBE2J2 may function in conjunction with other proteins like E3 ligases to form a complete complex required for the ubiquitination and subsequent degradation of target proteins.
Pathways
The enzyme UBE2J2 integrates with the ERAD pathway a significant component of the protein degradation system in cells. It also interacts with the ubiquitin-proteasome pathway which is important for degrading unwanted and misfolded proteins. UBE2J2 has shown interaction with several E3 ligases such as Hrd1 which facilitates the transfer of ubiquitin onto target substrates. This integration ensures the quality control of proteins within the ER.
Mutations or dysregulations in UBE2J2 can contribute to neurodegenerative diseases like Parkinson's disease due to its role in protein degradation. The impaired function and accumulation of misfolded proteins can exacerbate these conditions. Additionally cancer research has shown that overexpression of UBE2J2 might be linked to tumor progression such as in hepatocellular carcinoma. Its connection with proteins like p53 is critical as p53 is known to be a tumor suppressor and its regulation can be influenced by UBE2J2 activity.